We achieve success across all therapeutic areas and target demographics. We have the experience to serve as your next investigative site. Ask us for more information.

 

YearType% of GoalRandomizedEnrollment DaysRetention Rate
2023COVID-19TBD0TBDTBD
2023COVID-19TBD12TBDTBD
2023Influenza105%22TBDTBD
2023PneumococcalTBD0TBDTBD
2022RSV177%177TBDTBD
2022RSV96%23TBDTBD
2022Pneumococcal138%8393100%
2022Pneumococcal109%38813%
2022LymeTBD8TBDTBD
2022Influenza170%375TBDTBD
2022InfluenzaTBD1246TBD
2022Influenza84%6392100%
2022Dengue104%5294TBD
2022COVID-19112%4528TBD
2022COVID-1984%63190%
2022COVID-19185%376TBD
2022CMV37%20TBDTBD
2022Chikungunya135%54111TBD
2022Influenza130%2646TBD
2022COVID-19/FLU64%323691%
2022Pneumococcal77%23238100%
2021Chikungunya89%679493%
2021Chikungunya151%113TBD29%
2021COVID-1925%10TBD90%
2021COVID-19100%4033TBD
2021COVID-19100%12145100%
2021COVID-19112%2835TBD
2021COVID-19132%106TBDTBD
2021COVID-19100%2585TBD
2021COVID-19213%2132426%
2021COVID-19132%21281TBD
2021COVID-1990%36TBDTBD
2021COVID-19125%1003158%
2021Influenza136%1927TBD
2021Lyme425%119102TBD
2021RSV200%5056TBD
2021RSV134%134133TBD
2021RSV113%203123TBD
2021Yellow Fever168%96326TBD
2020HPV150%60340TBD
2020E Coli48%2422096%
2020COVID-19111%444135TBD
2020COVID-19192%772391%
2020Chikungunya101%14212092%
2020Rabies100%4018075%
2020COVID-19102%50990TBD
2020RSV100%30TBD100%
2020COVID-19162%38948TBD
2019C. Diff102%61425TBD
2019Influenza100%501100%
2019Pneumococcal100%4518100%
2019RSV103%15425100%
2019Pneumococcal108%409092%
2019Smallpox118%1776290%
2019C. Diff175%2115086%
2019E Coli112%769067%
2019Lyme101%7660100%
2019Lyme222%13327097%
2019Pneumococcal105%639498%
2019Pneumococcal100%58498%
2019RSV102%1786098%
2019MeningitisTBD16365100%
2018Pneumococcal120%4843100%
2018HPV100%335100%
2018Zika105.0%423292%
2018Dengue97.0%347287%
2018Avian Flu102%1224366%
2017Influenza95%10411873%
2017Influenza102%921687%
2017Influenza105%77899%
2017Cholera100%4011279%
2017Meningitis88%2217177%
2016Herpes193%2920073%
2016Avian Flu120%1804599%
2016Meningitis111%3047100%
2016Avian Flu124%8716 days86%
2015RSV129%24637100%
2015Pneumococcal128%3251100%
2015Pneumococcal100%208100%
2015Tetanus98%4480100%
2015Influenza117%10520100%
2015Ebola160%403995%
2014Influenza135%3036199%
2014Influenza100%6316100%
2014Influenza73%2220100%
2014Pneumococcal135%2724100%
2014Pneumococcal90%187294%
2014Norovirus102%563082%
2014Cholera157%1578093%
2014HPV100%33033%
2014Influenza102%827398%
2013Influenza100%701499%
2013Meningitis115%2319387%
2013Influenza100%493396%
2013Influenza95%5510594%
2013Smallpox170%196116100%
2013Influenza109%9810100%

Need more information? Send us a message here.

At Rochester Clinical Research, we are approaching 150 successful vaccine trials. We’re happy to boast a average enrollment  of goal of 116% and average retention rate of 98%. Over 9,000 volunteers have randomized into a vaccine trials at RCR. From pediatric to elderly, anthrax to pneumococcal, we continue to have success enrolling volunteers of all ages for all therapeutic areas.

2022 Vaccine Trials

In 2022, we randomized more than 1,400 volunteers across 18 vaccine trials. We’ve averaged a 113% enrollment of our goal. And our retention rates are on track to deliver the quality data our sponsors have asked of us.

 Vaccine Trial History by Age Group

See our Complete Vaccine Trial Statistics here.